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The Rb-related p107 protein has been implicated as an important control element in proper cell cycle
progression. The p107 protein is thought to restrict cellular proliferation in part through its interaction with
the E2F family of transcription factors and is, therefore, a specific target for regulation by several DNA viruses.
Here, we demonstrate that p107 protein levels are induced in a biphasic manner in human fibroblasts during
productive infection by the human cytomegalovirus (HCMV). Expression patterns of p107 protein levels during
HCMV infection of human embryonic lung cells (HELs) demonstrate a sustained induction from early to late
times of infection. We also demonstrate that the HCMV immediate-early protein IE1-72 complexes in vivo with
the p107 protein and that this interaction can be reconstituted in an in vitro system by using reticulocyte-
translated protein. Our data demonstrate that the interaction between p107 and the IE1-72 protein occurs at
times of infection that temporally match the second tier of p107 protein induction and the phosphorylation
pattern of the IE1-72 protein. Furthermore, we show here that the ability of p107 to transcriptionally repress
E2F-responsive promoters can be overcome by expression of the IE1-72 protein. This effect appears to be
specific, since the IE1-72 protein is not capable of relieving Rb-mediated repression of an E2F-responsive
promoter. Finally, our data demonstrate that HCMV infection can induce cellular proliferation in quiescent
cells and that IE1-72 expression alone can, to a degree, drive a similar progression through the cell cycle. These
data suggest that IE1-72-mediated transactivation of E2F-responsive promoters through alleviation of p107
transcriptional repression may play a key role in the cell cycle progression stimulated by HCMV infection.
Human cytomegalovirus (HCMV) is a ubiquitous betaher-
pesvirus that is rarely associated with disease in healthy adults
(42). Severe pathogenesis can occur, however, in immunocom-
promised individuals, transplant patients, and, in some cases,
pregnant women (for a review, see reference 42). Viral gene
expression during permissive HCMV infection of fibroblasts is
temporally regulated in a strict fashion, with a cascade of gene
activation progressing from immediate-early (IE) to early and
finally to late gene expression (61). The best-characterized and
most abundantly transcribed of the IE genes originate from a
series of spliced transcripts from the major IE region of the
HCMV genome under the control of the major IE promoter
(MIEP) (for reviews, see references 25 and 42). At least five
exons are alternatively spliced from the major IE region, re-
sulting in at least three major gene products which appear at
IE times. These gene products include the IE1-72 protein (a
72-kDa protein, also referred to as IE1 or IE72), the IE2-86
protein (an 86-kDa protein, also referred to as IE2 or IE84),
and the IE2-55 protein (a 55-kDa protein); all of these proteins
have the first three exons of the major IE region (exons 1 to 3)
in common, with exon 4 being unique to IE1-72 (resulting in a
2.0-kb transcript from the UL123 region), exon 5 being unique
to IE2-86 (2.25-kb transcript from the UL122 region), and an
alternatively spliced version of exon 5 being unique to IE2-55
(1.7-kb transcript from the UL122 region) (77).
IE1-72 and the IE2-86 are both nuclearly localized proteins
that have been demonstrated to have important roles in regu-
lating both viral and cellular gene expression. IE2-86 is a
strong repressor of the MIEP (8, 34, 56, 59, 67–69, 78) and has
been shown to transactivate a number of viral and cellular
promoters, a subset of which are associated with proliferation
and DNA replication (4, 14, 26, 29, 35, 51, 58, 62, 69, 72, 80,
83). The IE2-86 protein is a sequence-specific DNA-binding
protein with at least five described DNA-binding sites (1, 10,
45, 55, 59, 72); it has also been demonstrated to associate with
the TATA-binding protein of the TFIID subunit of the basal
transcription complex (6, 24, 29, 45, 46, 58, 74). Direct binding
of the IE2-86 protein to specific DNA sequences and interac-
tion of the IE2-86 protein with the TATA-binding protein are
thought to be the major mechanisms of IE2-86-mediated trans-
activation. Transcriptional activation by the IE2-86 protein has
been shown to be synergistically enhanced by IE1-72 expres-
sion, but the mechanism of this synergy is not fully understood
(17, 26, 30, 35, 51, 58, 62, 78, 80, 83).
IE1-72 is a strong activator of the MIEP and can stimulate
transcription from several viral and cellular promoters but is,
in general, a weaker and less promiscuous transactivator than
IE2-86 (2, 4, 9, 18, 26, 30, 51, 78, 82, 83). The IE1-72 protein
does not appear to bind DNA specifically and does not interact
directly with the TATA-binding protein. Proposed mecha-
nisms for IE1-72-mediated transactivation appear to involve
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both direct and indirect methods. Expression of the IE1-72
protein has been demonstrated to activate the MIEP of
HCMV through NF-kB sites in the promoter (70). However,
the mechanics of this activation are not clear and do not ap-
pear to involve direct protein-protein interaction between the
IE1-72 and NF-kB proteins. The IE1-72 protein has been
shown to directly bind the CCAAT-box binding protein CTF1,
resulting in activation of the TATA-less human DNA polymer-
ase a gene, a component of the host DNA replication machin-
ery (32). Deletion of the CCAAT box motif abolishes transac-
tivation of the promoter by the IE1-72 protein. Recent data
have also demonstrated that the IE1-72 protein can directly
activate human wild-type dihydrofolate reductase promoter,
another gene essential for DNA replication. Activation occurs,
at least in part, through the E2F sites in the promoter; the
IE1-72 protein was shown to be capable of binding the E2F-1
protein (60).
The p107 protein was first characterized as a host factor
associated with the viral transforming proteins E1A of adeno-
virus and the large T antigen of simian virus 40 (SV40) (20, 31,
88, 92). Regions of E1A and large T required for binding p107
overlap the regions required for viral protein interaction with
the tumor suppressor protein pRb, and mutations of the viral
proteins in this region have been demonstrated to prevent
transformation (7, 15, 16, 21, 47, 49, 84, 87, 88). Amino acid
sequences of p107, pRb, and the p130 protein have revealed a
strong homology between all of the proteins with a conserved
pocket region required for interaction with E2F, a het-
erodimeric family of transcription factors that play a key role in
stimulating cellular proliferation (22, 39, 43, 47, 48, 64). Bind-
ing of an E2F family member by one of the pocket proteins
creates an active complex which, when bound to an E2F site,
results in transcriptional silencing of the promoter (85, 86). In
normal cells, the interaction between the pocket proteins and
their E2F partners is tightly regulated and is a key to ensuring
proper cell cycle progression, with each pocket protein exert-
ing its influence at different stages in the cell cycle. Data from
numerous laboratories suggest that proper cell cycle progres-
sion requires a tightly regulated release of E2F from various
pocket-protein family members at distinct times during the cell
cycle (for a review, see reference 19).
The p107 protein, like the pRb protein, can act as a powerful
suppressor of cellular proliferation. Overexpression of the
p107 protein has been shown to growth arrest certain cell types
in G1 in a manner analogous but not identical to that of pRb
(94, 95). The mechanism for p107-mediated suppression is not
well understood but appears to be due, at least in part, to the
ability of p107 to repress transcription from E2F-responsive
promoters. This repression is thought to block the expression
of a series of genes associated with progression through the cell
cycle, including c-myc, c-myb, N-myc, dihydrofolate reductase,
thymidine kinase, DNA polymerase a, cyclin A, cyclin D1, and
cdc2 (5, 13, 33, 37, 63–66, 81, 91) and resulting in G1 growth
arrest and prevention of DNA replication.
Host factors like the p107 and pRb proteins that negatively
influence cellular proliferation become obvious targets for reg-
ulation by infecting DNA viruses that must activate cellular
DNA replication machinery for successful infection. SV40, ad-
enovirus, and the human papillomavirus (HPV) are all small
DNA tumor viruses which specifically alter the function of
both the p107 and pRb proteins through direct protein-protein
interactions with a virally encoded gene product (large T of
SV40, E1A of adenovirus, and E7 of HPV) (for a review, see
reference 54). Like all DNA viruses, HCMV requires a cellular
environment favorable to viral DNA replication, and mounting
evidence suggests that HCMV may create such an environ-
ment in much the same manner as that of the small DNA
tumor viruses. HCMV infection has been demonstrated to
initiate several of the hallmark changes brought on with infec-
tion by the small DNA tumor viruses. Recent data indicate that
HCMV infection induces alterations in E2F-complexes, func-
tional inactivation of the p53 gene product, and accumulation
of chromosomal damage in infected cells (23, 76, 82). At a
mechanistic level, the IE1-72 and IE2-86 proteins are capable
of functionally complementing an E1A deficient adenovirus
(35, 75, 80), and the IE2-86 protein has been demonstrated to
bind and functionally inactivate the p53 protein in much the
same manner as the adenovirus E1B and SV40 large T proteins
(76). The IE2-86 protein has also been shown to interact func-
tionally with the pRb protein in a fashion analogous to that of
the adenovirus E1A protein (11, 28). These data prompted us
to examine regulation of the p107 protein during infection by
HCMV.
We demonstrate here that p107 protein levels are induced at
early to late times of HCMV infection. Furthermore, the p107
protein is specifically targeted during infection for binding by
the IE protein IE1-72, with the result of this interaction being
alleviation of p107-mediated repression of E2F-responsive
promoters. Finally, our data demonstrate that HCMV infec-
tion induces cell cycle progression in quiescent fibroblasts, and
expression of the IE1-72 protein alone, to a degree, is also
capable of driving cellular proliferation. We believe that these
data represent a novel mechanism for IE1-72-mediated trans-
activation and that this transactivation may play a role in the
cell cycle stimulation seen during HCMV infection by activat-
ing a series of genes involved in proliferation and DNA repli-
cation. We believe that IE1-72 expression is involved in facil-
itating progression through the cell cycle and subsequent viral
DNA replication in infected cells.
MATERIALS AND METHODS
Cell culture and infection. Human embryonic lung fibroblasts (HELs) and
human tumor cell line C33A cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (GIBCO-BRL,
Gaithersburg, Md.) and penicillin-streptomycin at 378C in a 5% CO2 incubator.
Infection with the HCMV Towne strain, passages 36 to 39, was performed as
described previously (41). A multiplicity of infection of 2 was used for all exper-
iments. Cells and virus were incubated for 90 min at 378C in a 5% CO2 incubator.
Free virus was washed off, and DMEM with heat-inactivated 4% fetal bovine
serum (GIBCO-BRL) was added to the infected cells.
Preparation of cell lysates for Western analysis and immunoprecipitation.
HELs were harvested at various hours postinfection (hpi). Cells were pelleted by
low-speed centrifugation and were washed twice with phosphate-buffered saline
(PBS). Cells were incubated in an EBC buffer (0.05 M Tris-HCl [pH 8.0], 0.12 M
NaCl, 0.5% Nonidet P-40, 0.1 M NaF, 0.2 mM Na-orthovanadate, 1 mM phen-
ylmethylsulfonyl fluoride) at 48C for 1 h, with leupeptin and aprotinin added at
10 mg/ml. Microcentrifugation for 20 min at 48C was used for clarification.
Supernatant was removed, and protein concentrations were determined with the
Bio-Rad (Richmond, Calif.) protein assay kit.
Western blot (immunoblot) analysis. Equal protein amounts of lysates per
time point (approximately 100 mg) were mixed in Laemmli sodium dodecyl
sulfate (SDS) sample buffer and were loaded onto SDS-polyacrylamide gels. A
duplicate gel was run and Coomassie stained to ensure equal protein loading.
Proteins were separated by electrophoresis and transferred overnight at 18 V to
Immobilon-P Transfer Membrane (Millipore, Bedford, Mass.) blots. The blots
were blocked for 1 h in 5% (wt/vol). Carnation nonfat dry milk dissolved in PBS.
The blots were then probed with primary antibody (the p107 monoclonal anti-
body was purchased commercially [Santa Cruz Biotechnology, Santa Cruz, Cal-
if.]; the IE protein antibodies were raised to nonconserved domains in the IE1-72
and IE2-86 proteins and have been described previously [76]) for 1 h in PBS
(1:200 dilution for p107; 1:1,000 dilution for IE proteins). The blots were washed
four times with PBS–0.1% Tween 20. After washing, the blots were probed with
secondary antibody (horseradish peroxidase-conjugated anti-mouse immuno-
globulin G [Sigma, St. Louis, Mo.]). The blots were again washed extensively in
PBS–0.1% Tween and were developed by enhanced chemiluminescence (Amer-
sham, Buckinghamshire, England) according to the manufacturer’s specifica-
tions.
Immunoprecipitations. Immunoprecipitations were performed at 48C. Equal
amounts of protein lysates (approximately 200 mg of infected cell lysate) were
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precleared for 1 h with Pansorbin cells (CalBiochem, La Jolla, Calif.). Mono-
clonal antibody (1:100 dilution) and 30 ml of protein G beads (Pharmacia,
Uppsala, Sweden) were added, and the volume was increased to 0.5 ml with
ELB1 buffer (0.25 M NaCl, 0.1% Nonidet P-40, 0.05 M N-2-hydroxyethylpipera-
zine-N9-2-ethanesulfonic acid [HEPES; pH 7.0], 1 mM phenylmethylsulfonyl
fluoride, 5 mM ethylenedinitroltetraacetic acid, 0.5 mM dithiothreitol). The
incubation was performed at 48C for 4 h with constant mixing. Beads were spun
down and washed six times with ELB1 buffer. The beads were mixed with
Laemmli buffer and boiled. Supernatant was run on SDS-polyacrylamide gel
electrophoresis (PAGE) gels. Western analysis (performed as described) was
used for detection of proteins in the immunoprecipitated complexes.
Immunoprecipitations of 35S- and 32P-labeled lysates. Infected HELs were
pulsed for 1 h with either [35S]methionine or 32Pi in DMEM without methionine
or phosphate, respectively, before harvesting (24). Lysates were immunoprecipi-
tated with the Dupont monoclonal antibody to the common region of the IE1-72
and IE1-86 proteins. Immunoprecipitation and detection were performed as
described.
Plasmids. The IE1-72 and IE2-84 expression vectors (pcDNA3IE1 and
pcDNA3IE2) have been previously described (93). The adenovirus E2CAT and
the E2CAT mutant were gifts from Steven Bachenheimer and have been de-
scribed previously (57). The p107 expression vector (p107CMVneo) and the
p107 vector used for transcription-translation (pBSKIIp107) were obtained from
Liang Zhu (95).
In vitro interactions. All transcription-translation of proteins was done with
the Promega TnT-coupled reticulocyte lysate system (Madison, Wis.) for
[35S]methionine labeling. The manufacturer’s protocol was followed. Simulta-
neous cotranslation of the IE1-72 and p107 proteins was carried out to demon-
strate in vitro interaction. Immunoprecipitations were performed with 5 ml of
translated protein, 20 ml of protein G beads, and 0.5 mg of antibody in 0.3 ml of
ELB1 buffer. The reactions were allowed to proceed overnight, and the beads
were washed extensively (five times with ELB1) before boiling and separation by
SDS-PAGE. The gels were dried and exposed to film.
Transfections and CAT assays. C33A cells were transfected by the GIBCO-
BRL Lipofectamine kit. C33A cells were grown in 100-mm dishes and trans-
fected at 70% confluency. A total of 5 mg of DNA was used in each transfection
mixture with empty pGEX-7 DNA used to normalize total DNA amounts; 1 mg
of reporter and 1 mg of each expression vector indicated were used. DNA was
suspended in 300 ml of DMEM and was mixed with 300 ml of DMEM containing
6 ml of Lipofectamine reagent. The DNA-Lipofectamine complexes were al-
lowed to form at room temperature for 45 min. The cells were washed with 4 ml
of DMEM. The complexes were brought up to 2.4 ml with DMEM-H and added
to the cells. After 12 h, 4 ml of DMEM-H with 12% fetal bovine serum (GIBCO)
was added to the cells; after 24 h, medium was replaced with fresh DMEM with
10% fetal bovine serum (GIBCO). Cells were harvested, and chloramphenicol
acetyltransferase (CAT) assays were performed as described previously (27) with
an SV-bGAL (Promega) internal control used to standardize activity.
Induction of cell cycle progression by HCMV infection or IE gene expression.
Primary medical research council (MRC5) human fibroblasts were serum starved
for 6 days and then mock infected or infected with either HCMV at 10 PFU per
cell or UV-irradiated HCMV for 2 h. Virus was washed off with serum-free
media, and the cells were analyzed by propidium iodide staining and fluores-
cence-activated cell sorter (FACS) analysis. COS-1 cells were serum starved for
6 days and transfected by Lipofectin with PHK3 (an SV40 control vector),
pSG5IE1 (an SV40-driven IE1-72 expression vector), or HM121 (an SV40-
driven IE2-86 expression vector) (30). The cells were analyzed 2 days posttrans-
fection. Transfection efficiencies were 20% for IE1-72 and 5% for IE2-86.
RESULTS
Protein expression of p107 during HCMV infection of HELs
is biphasic. HCMV infection has been demonstrated to alter
levels of a number of cellular factors involved in regulating
proliferation (4, 14, 26, 29, 35, 51, 58, 62, 69, 72, 80, 83). Recent
data have shown that HCMV specifically targets the tumor
suppressor protein Rb for regulation in much the same manner
as do the small DNA tumor viruses (11, 28). Since regulation
of the Rb protein during infection by DNA viruses accompa-
nies a similar regulation of the closely related p107 protein, we
chose to examine the effect of HCMV infection on p107 ex-
pression. To examine protein levels of p107 during HCMV
infection, cell lysates were prepared at various times postin-
fection and Western analysis was performed as described. An
initial induction (over mock infection) was seen at 0 hpi (Fig.
1, lanes 1 and 2), but this induction was no longer detectable by
4 hpi (Fig. 1, lane 3); a second tier of protein induction was
visible beginning at approximately 16 hpi and persisting
through late times of infection (72 hpi), with maximal expres-
sion occurring at 24 hpi (Fig. 1, lanes 5 through 8). Identical
results were obtained when a polyclonal antibody to p107 (San-
ta Cruz) and a second monoclonal antibody (a generous gift
from David Livingston) to p107 were used (data not shown).
The sustained induction seen at early to late times of infection
is probably the result of direct viral regulation at the transcrip-
tional, translational, or posttranslational level. These data
clearly demonstrate that p107 protein levels are specifically
regulated by HCMV infection. It should be noted that tempo-
rally, the second tier of p107 protein induction (beginning at 16
hpi and being maximal at 24 hpi) coincides with the first peak
of viral DNA replication in fibroblasts (61). A Coomassie stain
of the samples is included to demonstrate equivalent protein
loading (Fig. 1B).
IE1-72 and p107 protein complex formation occurs in
HCMV-infected HELs. Regulation of p107 by adenovirus,
SV40, and HPV occurs primarily through direct protein-pro-
tein interaction between the p107 protein and a virally encoded
gene product (54). To establish whether the HCMV IE1-72
protein formed a complex with the p107 protein during HCMV
infection, immunoprecipitations were performed from
HCMV-infected lysates with a p107-specific monoclonal anti-
body. We demonstrate that complexes containing p107 immu-
noprecipitated from HCMV-infected lysates (24 hpi) also con-
tained the IE1-72 protein (Fig. 2A, lane 4) but not the IE2-84
protein (Fig. 2B, lane 3), as determined by Western blot anal-
ysis with monoclonal antibodies specific to IE1-72 and IE2-84,
respectively. Furthermore, immunoprecipitations of p107-con-
taining complexes from mock-infected cell lysate failed to con-
tain the IE1-72 protein (Fig. 2A, lane 3), confirming that the
band detected at 72 kDa in infected lysates is indeed a viral
protein. All experiments were repeated with a Santa Cruz
polyclonal antibody to p107 and a second monoclonal antibody
obtained from David Livingston, with identical results (data
not shown). It has been previously demonstrated that the
IE2-86 protein interacts with the Rb protein both in vitro and
FIG. 1. Protein levels of p107 during HCMV infection of HELs. HELs were
infected or mock infected as described. (A) At different hpi cells were harvested,
cell lysates were prepared, and equal amounts of lysate (approximately 200 mg)
were separated by SDS-PAGE and transferred to an Immobilon membrane.
Western blot analysis was performed with an anti-p107 monoclonal antibody
(Santa Cruz). (B) A Coomassie stain of samples run was included to demonstrate
equal protein loading.
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in vivo but does not appear to bind the p107 protein (10, 26).
To our knowledge, this represents the first system described in
which two distinct viral proteins interact exclusively with two
separate members of the pocket protein family (IE1-72 with
p107 and IE2-86 with pRb). The p107 and pRb proteins ap-
pear to exert their effects at different points during the cell
cycle; distinct targeting of the proteins by viral factors could be
construed as a mechanism evolved by the virus to temporally
control its functional inactivation of the pocket protein family,
thereby allowing a more regulated progression through the cell
cycle.
The IE1-72 and p107 proteins interact in vitro. We wished
to confirm the in vivo data obtained on the complex formation
between the p107 and IE1-72 proteins by reconstituting the
interaction in an in vitro assay. We used a rabbit reticulocyte
protein expression system to in vitro translate and methionine
label the IE1-72 and p107 proteins and then assayed for inter-
action. The antibodies used for immunoprecipitation of the
translated proteins (monoclonal antibodies to the IE1-72 and
the p107 proteins, respectively) recognize their specific in
vitro-translated product and fail to cross-react with the other
proteins (Fig. 3A, lanes 1 to 4). Here, we demonstrate that
when IE1-72 and p107 genes are cotranslated, immunoprecipi-
tation of p107 coprecipitates the IE1-72 protein (Fig. 3A, lane
5). We included a control demonstrating half of the total input
protein used in the immunoprecipitations; it should be noted
that the levels of translation for p107 were very low compared
with the translation levels for IE1-72 (Fig. 3B). We have been
unable to coimmunoprecipitate the IE1-72 and p107 proteins
using a monoclonal antibody to the IE1-72 protein but have
been able to do so using a polyclonal antibody (data not
shown), suggesting that the epitope of the IE1-72 recognized
by the monoclonal antibody may be masked by interaction with
p107. These data demonstrate that the interaction can be re-
created in vitro and that the interaction does not require the
presence of additional viral proteins.
IE1-72 and p107 complex formation occurs at early to late
times of HCMV infection in HELs. We wished to determine
FIG. 2. In vivo interaction between the HCMV IE1-72 protein and the cel-
lular p107 protein. p107 protein was immunoprecipitated from mock- and
HCMV-infected cellular lysate (approximately 200 mg) by mixing protein A
beads and anti-p107 monoclonal antibody (Santa Cruz) with lysate for 4 h at 48C.
The beads were washed extensively with ELB1 buffer, and bound protein was
boiled off and separated on SDS-PAGE and transferred to Immobilon. The blots
were analyzed by Western blotting for IE1-72 or IE2-86 protein to determine
coimmunoprecipitation between the p107 protein and the IE proteins of HCMV.
(A) Immunoprecipitated (IP) complexes were analyzed by Western blotting for
IE1-72 protein. Lanes: 1 and 2, mock-infected and 24-hpi-infected lysate (20 mg)
as negative and positive controls for IE1-72 protein, respectively; 3 and 4, p107
protein immunoprecipitated from mock- or HCMV-infected (24 hpi) cells, re-
spectively; 5 and 7, negative controls with in vitro-translated pRb and IE2-86
protein; 6, a positive control of in vitro-translated (IVT) IE1-72 protein. The blot
was analyzed by Western analysis for the IE1-72 protein. (B) Identical immu-
noprecipitated (IP) complexes were analyzed by Western analysis for the IE2-86
protein. Lanes: 1 and 2, 24-hpi- and mock-infected lysate as positive and negative
controls for IE2-86 protein, respectively; 3 and 4, immunoprecipitations of the
p107 protein from HCMV-infected (24 hpi) and mock-infected cells, respec-
tively; 6 and 7, glutathione S-transferase (GST) fusion proteins of the IE1-72
protein and the Rb protein as negative controls; 5, a GST–IE2-86 protein run as
a positive control.
FIG. 3. In vitro interaction between the IE1-72 protein and the p107 protein.
The Promega TnT system ([35S]methionine labeled) was used for in vitro trans-
lation; the p107 and IE1-72 proteins were cotranslated to test for interaction. (A)
The IE1-72 protein was immunoprecipitated with monoclonal antibody to the
IE1-72 protein (lane 1) but not with monoclonal antibody to the p107 protein
(lane 2). The p107 protein was immunoprecipitated with monoclonal antibody to
the p107 protein (lane 4) but not with monoclonal antibody to the IE1-72
protein. Monoclonal antibody to the p107 antibody was used to coimmunopre-
cipitate both the IE1-72 and p107 proteins (lane 5). (B) One-half of total input
levels of translated proteins used.
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the temporal kinetics of the interaction occurring between the
p107 and IE1-72 proteins. Immunoprecipitations against the
p107 protein were done over a time course of HCMV infection
to determine the kinetics of this complex formation during
infection. Complexes containing both the IE1-72 and the p107
proteins are not observed until 16 hpi, become maximal at 24
hpi, and remain detectable until late times of infection (Fig. 4,
lanes 3 through 6). The temporal kinetics of IE1-72 and p107
interaction matches almost identically with the second tier of
p107 protein induction seen during HCMV infection (Fig. 1).
It is possible that the high levels of p107 protein detected are
a consequence of the interaction between the IE1-72 and the
p107 proteins. The IE1-72 protein may trigger induction of
p107 protein levels by acting at the transcriptional or transla-
tional level. Again, it should be noted that the time of maximal
interaction between the p107 and IE1-72 proteins (24 hpi)
coincides temporally with the initial peak of viral DNA repli-
cation seen during HEL infection.
IE1-72 protein expression patterns during HCMV infection
of HELs. The IE1-72 protein is in abundance at IE times of
infection, and protein levels are stable through late times of
infection (Fig. 5C, lanes 3 through 8). Immunoprecipitation of
IE1-72 from [35S]methionine-labeled infected cell lysates
shows IE1-72 synthesis occurring by as early as 4 hpi, but new
synthesis is absent at later times of infection (Fig. 5A, lane 2).
By comparison, IE2-84 protein expression and synthesis are
detectable at 4 hpi and continue throughout infection (Fig.
5A). Therefore, it is interesting that the interaction between
the IE1-72 protein and the p107 protein is minimal at 16 hpi
and does not become maximal until 24 hpi (Fig. 4, lanes 3 and
4), even though IE1-72 protein levels are high at earlier times
of infection (Fig. 5C, lanes 3 to 5). These results suggest that
elevated protein levels of IE1-72 and p107 do not alone appear
to be sufficient to drive the interaction. Phosphorylation pat-
terns for the IE1-72 protein in HELs show low levels of phos-
phorylation at IE times of infection, maximal phosphorylation
at 24 hpi, and gradual decrease at later times of infection (Fig.
5B, lanes 2 through 6). The temporal kinetics for IE1-72 phos-
phorylation closely match the times when the IE1-72 and p107
protein interaction is detectable. Even though new phosphor-
ylation of IE1-72 decreases after 24 hpi (Fig. 5B, lane 4), stable
phosphorylated IE1-72 protein could account for the contin-
ued interaction with p107. These data suggest that the phos-
phorylation status of the IE1-72 protein may be a key regula-
tory element in determining complex formation with the p107
protein.
IE1-72 protein expression is sufficient to alleviate p107 sup-
pression of an E2F-responsive CAT reporter construct. An
E2F-responsive promoter derived from the adenovirus early
gene 2 promoter with the ATF sites mutated (Fig. 6A) was
used as the reporter construct for all CAT assays. In a C33A
cell line, constitutive levels of transcription from the reporter
were easily detectable; the mutant E2CAT reporter (mutations
in the promoter inactivated the E2F sites) had no activity even
when cotransfected with the IE1-72 expression vector (Fig. 6B,
lanes 2, 3, and 4). E2CAT reporter activity was not significantly
altered when the IE1-72 expression vector was cotransfected
with the E2CAT reporter, suggesting that IE1-72 expression
was not capable of further transactivating this promoter in the
C33A cell line (Fig. 6B, lane 5).
The p107 protein has been demonstrated to repress tran-
scription off an E2F-responsive promoter (71, 94). This effect is
presumably due to active transcriptional repression by the
p107-E2F complex bound to the E2F sites in the promoter. We
demonstrate here that p107 transcriptional repression is re-
versible by coexpression of the IE1-72 protein. Activity
dropped approximately sixfold when the E2CAT reporter was
cotransfected with a p107 mammalian expression vector (Fig.
6B, lane 6). When 1 mg of both the IE1-72 and the p107
expression vectors was cotransfected with the E2CAT pro-
moter, activity was restored to approximately two-thirds of
constitutive levels (Fig. 6B, lane 7). When the amount of the
IE1-72 expression vector cotransfected was increased to 2 mg,
full promoter activity was restored (Fig. 6B, lane 8). These data
demonstrate that even though in C33A cells the IE1-72 protein
is not capable of further activating an E2F promoter, it is
capable of relieving p107-mediated transcriptional repression.
FIG. 4. Interaction between the IE1-72 and p107 proteins occurs at early to
late times of infection. Coimmunoprecipitation of the p107 and IE1-72 proteins
was performed (as described in the legend to Fig. 2) at various times postinfec-
tion.
FIG. 5. Temporal posttranslational modification of the IE1-72 and IE2-86
proteins in HELs. HCMV-infected HELs were pulse-labeled with [35S]methi-
onine or 32Pi 1 h prior to harvesting. The IE1-72 and IE2-86 proteins were
immunoprecipitated with a monoclonal antibody to a conserved domain in both
proteins (Dupont IE monoclonal antibody). Immunoprecipitated complexes
were analyzed by SDS-PAGE; [35S]methionine immunoprecipitates were en-
hanced with 1 M sodium salicylate. Gels were exposed to X-ray film and devel-
oped. (A) [35S]methionine pulse-labeling of infected cells was used to detect de
novo synthesis of the IE1-72 and IE2-86 proteins. (B) 32Pi pulse-labeling of
infected cells was used to detect phosphorylation of the IE1-72 and IE2-86
proteins. (C) Protein levels of the IE1-72 protein during HCMV infection, as
determined by Western analysis. Western analysis was performed as described in
the legend to Fig. 1 with a monoclonal antibody to the IE1-72 protein.
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We have obtained similar data in a DG75 cell line, a non-
Epstein-Barr virus Burkitt’s lymphoma cell line (data not
shown).
Expression of the IE1-72 protein in human glioblastoma
cells has been demonstrated to transactivate an E2CAT re-
porter (60), while our data demonstrate no transactivation in
C33A cells. We have reasoned that this may be due to the lack
of functionally active pocket-protein complexes in C33A cells.
In normal cycling cells, E2F-responsive promoters are main-
tained in a transcriptionally silent form through E2F-pocket
protein complexes bound to the E2F sites in the promoter.
Since C33A cells lack a functional Rb protein, high levels of
E2F transcriptional activity persist. This would account for the
high levels of constitutive reporter activity detected (constitu-
tive E2CAT promoter activity was close to 50% acetylation). In
this type of system, an indirect form of activation, such as the
alleviation of repression by the IE1-72 protein which we see,
might be masked by the constitutively high level of activity off
the E2CAT reporter construct. In a cell line in which E2F
complexes were transcriptionally repressed at most times dur-
ing the cell cycle, such as glioblastoma cells, alleviation of
suppression of even just a subset of those complexes could
have a dramatic effect on activation.
The IE1-72 protein is incapable of alleviating Rb-mediated
repression of an E2F-responsive CAT reporter construct. The
pRb and p107 proteins appear to be functionally identical in
their ability to suppress transcription from E2F-responsive
promoters. We wished to determine whether alleviation of
repression of an E2F-responsive promoter by the IE1-72 pro-
tein extended to Rb-mediated repression or was specific only
to p107 suppression. The constitutive activity of the E2CAT
promoter was reduced by approximately fourfold when the
promoter was transfected with a pRb expression construct
(Fig. 7, lane 4). Cotransfection of the E2CAT promoter with
both the pRb expression vector and the IE1-72-kDa expression
vector failed to restore promoter activity (Fig. 7, lane 5). These
data indicate that the HCMV IE1-72 protein is capable of
relieving p107-mediated suppression of an E2F-responsive
promoter but not Rb-mediated repression of the same pro-
moter. Since the IE1-72 protein fails to interact physically with
pRb (Fig. 2B), we reason that protein-protein interactions are
FIG. 6. Alleviation of p107-mediated repression of the E2CAT reporter by
IE1-72 expression. Transfections were done with the Lipofectamine kit from
GIBCO-BRL by using C33A cells with an internal b-galactosidase control used
to standardize for transfection efficiency. The reporter and indicated expression
vectors were all used at 1 mg per transfection. All expression vectors were driven
by the CMV MIEP. (A) Schematic representation of the E2CAT reporter with
the ATF sites mutated and the E2CAT E2F2 reporter with the E2F sites
mutated. (B) CAT assay of C33A cells transfected with the E2CAT reporter
construct and various expression vectors. Constructs used are defined as follows:
no DNA, cells alone; mt E2CAT, the E2CAT promoter minus the ATF sites with
the E2F sites mutated; E2CAT, the E2CAT promoter minus the ATF sites;
IE1-72, a CMV-driven IE1-72 eukaryotic expression vector; and p107, a CMV-
driven p107 eukaryotic expression vector. Unless otherwise noted, 1 mg was used
for each construct. All CAT assays were done at least three times.
FIG. 7. IE1-72 expression does not alleviate Rb-mediated repression of the
E2CAT promoter. Transfections were done as described in the legend to Fig. 6,
with identical amounts of DNA used. The constructs used were also identical to
those in Fig. 6, with the exception of Rb, a CMV-driven Rb eukaryotic expression
vector. All CAT assays were done at least three times.
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involved in the ability of the IE1-72 protein to relieve suppres-
sion of these types of promoters.
HCMV infection induces cell cycle progression in quiescent
cells. DNA viruses require host cellular machinery in order to
replicate their own viral DNA for successful infection. For this
to occur, viruses have had to evolve a means of activating their
typically quiescent target cells to stimulate exit of G0/G1 and
entry into the cell cycle. Infected cells would be pushed from
G0/G1 into the cell cycle, allowing for activation of the cellular
DNA replication machinery in the ensuing S phase and sub-
sequent viral DNA replication. HCMV, which encodes many
of its own DNA replication-associated genes, is, nevertheless,
dependent on a series of host factors to allow for viral DNA
replication; therefore, we wished to determine whether
HCMV infection did indeed result in cell cycle progression.
Serum-starved fibroblasts (arrested in G0/G1) were mock in-
fected, infected with HCMV, or infected with irradiated (in-
activated) HCMV. Cells were harvested and examined for
entry into S phase by propidium iodide staining and flow cy-
tometry. All infections were done in the absence of serum. At
60 hpi, a dramatic shift from G0/G1 to S phase and G2/M was
observed in the HCMV-infected cells, with the percentage of
fibroblasts in S phase increasing from 3.2% in the serum-
starved fibroblasts to 17.8% in the HCMV-infected cells and
the percentage of cells in G2/M increasing to 14.2% in the
HCMV-infected cells from 6.0% in the serum-starved cells
(Fig. 8A, I and II). The infection with UV-irradiated virus,
however, showed little shift into G0/G1, with only 4.7% of the
cells in S phase and 8.6% of the cells in G2/M demonstrating
that serum or binding and entry of virus alone is not sufficient
to induce cell cycle progression (Fig. 8A, I and III). These data
are consistent with other observations of HCMV driving cell
cycle progression in infected cells (44). Clearly, HCMV infec-
tion is capable of overcoming a serum starvation-induced
G0/G1 block to stimulate cellular proliferation.
To determine whether expression of the IE proteins IE1-72
and IE2-86 was capable of recreating this effect, expression
vectors of the IE proteins were transfected into G0/G1-arrested
COS-1 cells (cells were arrested by 6 days of serum starvation).
At 2 days posttransfection, cells transfected with an expression
vector for the IE1-72 protein showed a modest increase in the
number of cells in S phase (with 7.8% in the cells transfected
FIG. 8. HCMV infection and IE1-72 and IE2-86 expression induce cell cycle changes in quiescent cells. (A) MRC5 fibroblasts were serum starved for 6 days and
then mock infected (I), infected with HCMV (10 PFU per cell) (II), or infected with UV-inactivated HCMV (III). Infections were performed for 2 h, and then the
cells were washed with serum-free medium. After 60 h, the cells were propidium iodide stained and analyzed by FACS analysis. (B) COS-1 cells were serum starved
for 6 days and transfected with either an empty expression vector (I), an IE1-72 expression vector (II), or an IE2-86 expression vector (III). Staining and analysis was
performed as described for the MRC5 cells. Transfection efficiencies for the IE1-72 and IE2-86 expression vectors were 20 and 5%, respectively.
VOL. 70, 1996 THE IE1-72 PROTEIN INTERACTS WITH THE p107 PROTEIN 7873
with vector alone compared with 10.0% in the cells transfected
with an IE1-72 expression vector [an induction in the number
of cells in S phase of almost 25%]) and a more dramatic
increase in the number of cells in G2/M (from 21.8% of cells
transfected with vector alone compared with 26.4% in IE1-72-
transfected cells) (Fig. 8B, I and II). IE2-86 expression resulted
in a progression into S phase more dramatic than that seen
with IE1-72 expression (from 7.8% in the cells transfected with
vector alone to 11.9% in the IE2-86-transfected cells); how-
ever, a similar increase in the number of cells in G2/M was
observed (from 21.8% in the cells transfected with vector alone
to 25.9% in the IE2-86-transfected cells) (Fig. 8B, III). All of
the increases seen with the transfected IE expression vectors
were highly reproducible. Expression of the IE1-72 and IE2-86
proteins can induce shifts in the cell cycle state of quiescent
cells; however, the effect does not seem as pronounced as that
seen with complete HCMV infection. These data suggest that
both the IE1-72 and IE2-86 proteins play a role in inducing
cellular proliferation during infection but that other factors
employed by HCMV are also necessary.
DISCUSSION
Creation of a cellular environment favorable to DNA repli-
cation is a common motif which appears to occur through
similar mechanisms among different small DNA tumor viruses
(SV40, HPV, and adenovirus). Data increasingly indicate that
HCMV functions in a manner analogous to these viruses with
respect to stimulating host cell DNA replication; however, the
mechanisms that HCMV employs to activate cellular replica-
tion machinery have not yet been fully elucidated. The p107
protein has been shown to have a key role in preventing cel-
lular proliferation and, therefore, becomes a focus for regula-
tion by the small DNA viruses. We wished to determine
whether HCMV infection resulted in a similar targeting of the
p107 protein. Western blot analysis of p107 in HCMV-infected
fibroblasts reveals an induction of protein levels during a time
course of infection, with sustained elevation of protein de-
tected from early to late times of infection. We demonstrate
that the IE1-72 protein can complex with the p107 protein in
HCMV-infected HELs and that this interaction coincides with
the p107 protein induction seen at early to late times of infec-
tion. The interaction also coincides with maximal levels of
IE1-72 phosphorylation, leading us to speculate that phosphor-
ylation of IE1-72 might be necessary for the interaction to
occur, an avenue of research we are currently investigating.
The IE1-72 protein is capable of relieving the p107-medi-
ated transcriptional repression of an E2F-responsive pro-
moter. We believe that this effect is dependent on complex
formation between the HCMV IE1-72 protein and the p107
repressor gene product. We base this assertion on the fact that
pRb, which we and others have demonstrated does not com-
plex with the IE1-72 protein, represses the E2CAT reporter in
a manner similar to that of p107 but is resistant to alleviation
of repression by IE1-72 expression. We believe that these data
represent a novel mechanism for transcriptional activation by
the IE1-72 protein, involving the overcoming of p107-mediated
repression; however, details of this mechanism need to be
further elucidated. We hypothesize that p107 is released from
its E2F binding partner (presumably E2F4) upon complex for-
mation with the phosphorylated form of the IE1-72 protein,
thereby allowing transcriptional activation by E2F in a manner
analogous to phosphorylation of p107 (3, 79) (Fig. 9, III);
however, data from our laboratory supporting this model are
still preliminary. It should be noted that earlier work demon-
strated an initial induction of a complex with E2F activity
containing p107 at IE times of infection, but the IE1-72 protein
could not be detected in the complex (82). We suspect that this
complex may be disrupted by the IE1-72 protein at early to late
times of infection, but it is also possible that the IE1-72 protein
stabilizes the complex and alleviates its repressive function to
allow for transcription (Fig. 9, II).
A series of HCMV early promoters contain E2F sites (50,
52, 90), suggesting that E2F plays an important role in activa-
tion of viral genes, but we speculate that the role of E2F during
HCMV infection is not limited to activation of viral promoters
only. The first round of viral DNA replication occurs at a time
during infection when the interaction between the p107 and
IE1-72 proteins is maximal. Because this interaction is maxi-
mal, concomitant with viral replication, and because a series of
genes that contain E2F-responsive elements in their promoters
are associated with the cellular DNA replication machinery, a
potential function of IE1-72 and p107 protein complex forma-
tion beyond activation of viral promoters can be hypothesized.
The p107 protein is known to repress E2F-responsive promot-
ers, a subset of which are involved in DNA replication and
turned on during HCMV infection (dihydrofolate reductase,
thymidine kinase, and DNA polymerase a) (4, 14, 26, 29, 35,
51, 58, 62, 69, 72, 80, 83), and our data demonstrate that IE1-72
expression is capable of overcoming p107-mediated repression.
It is, therefore, possible that the IE1-72 protein promotes tran-
scriptional activation of these promoters, thereby activating
cellular DNA machinery and allowing viral DNA replication to
occur. Interestingly, the p107 promoter itself contains E2F
sites which can be repressed by p107 (96). The induction of
FIG. 9. A model of HCMV IE1-72 and p107 protein-protein interaction.
Active transcriptional repression is mediated by p107 (I). Binding of the IE1-72
protein (which may be based on the phosphorylation state of the IE1-72 protein)
relieves transcriptional repression of an E2F-responsive promoter by the p107
protein (II). Alleviation of repression may involve release of p107 from its E2F
binding partner (III), but data supporting this model are still preliminary. Tran-
scriptional activation of the E2F-responsive genes would result in activation of
host cellular DNA machinery and allow for viral DNA replication.
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p107 protein levels seen during infection may, therefore, be
due, at least in part, to activation of the p107 promoter through
alleviation of repression by IE1-72 protein expression.
Growing evidence has suggested a common mechanism for
activating the host DNA replication machinery by small DNA
tumor viruses. These viruses all seem to induce cellular prolif-
eration and movement into S phase through direct protein-
protein interactions between virally encoded proteins and a
subset of host proteins. Cellular targets for regulation by viral
proteins expressed by the small DNA tumor viruses include the
E2F-regulating family of pocket proteins, pRb, p107, and p130.
In the case of these viruses, large T, E7, and E1A all interact
with both p107 and pRb. Interestingly, the IE protein IE2-86 of
HCMV has been demonstrated to bind the Rb protein (93),
while our data indicate that the IE1-72 protein (but not the
IE2-86 protein) interacts specifically with the p107 protein.
Therefore, HCMV represents a novel system in which two
distinct viral proteins target the p107 and pRb proteins sepa-
rately for regulation through direct protein-protein interaction.
The outcome of HCMV viral protein interaction with both
pRb and p107 seems to be an activation of transcription from
promoters normally repressed by the pocket proteins. Since
both the IE1-72 and the IE2-86 proteins are expressed in a
temporally distinct fashion during infection, it seems reason-
able to speculate that alleviation of Rb-mediated or p107-
mediated transcriptional repression would be similarly regu-
lated. HCMV therefore appears to have a level of control in
activating E2F-responsive promoters at various stages of infec-
tion finer than that of the small DNA tumor viruses which
encode a single gene product to bind all members of the pocket
protein family.
The biological ramifications of this extra level of control are
not completely clear, but the high levels of transformation
associated with infection by the small DNA tumor viruses that
are absent from HCMV infection may be a function of this.
Transformation by the small DNA tumor viruses seems to
occur through two pathways: in one, a viral protein binds all of
the pocket protein family members (pRb, p107, and p130),
resulting in activation of E2F-responsive promoters. The
E2F-1 promoter is itself activated, creating an amplification of
E2F-1 protein levels. Increased levels of E2F-1 promote cel-
lular proliferation but have also been demonstrated to activate
p53-mediated apoptosis (38, 53, 73). Therefore, in the second
pathway, a viral protein targets and functionally inactivates
p53, preventing the apoptotic pathway from being successfully
triggered. In most infections, proliferation allows for replica-
tion of the viral DNA and successful infection, but a minority
of infections are aberrant, resulting in unchecked proliferation
and eventual transformation. It has been shown that HCMV
infection induces the p53 gene product in a manner analogous
to adenovirus and SV40 infection, that the IE2-86 protein can
directly bind the p53 protein and prevent p53-mediated tran-
scription (76), and that HCMV proteins (the IE72 and IE2-86
proteins) can protect against apoptosis (40). Our data also
demonstrate that HCMV can induce cellular proliferation and
that the IE1-72 and IE2-86 proteins seem to be functionally
similar to the adenovirus E1A, the SV40 large T, and the HPV
E7 viral proteins in their ability to bind pRb and p107 and, by
extension, in their ability to stimulate cellular proliferation. It
is, therefore, interesting that a strong association between
HCMV infection and human cancer in infected patients has
never been demonstrated, even though both the small DNA
tumor viruses and HCMV target cellular pathways which can
lead to transformation. Our data point to what may be a crucial
difference: HCMV encodes at least two IE proteins to specif-
ically interact with different pocket proteins. Since these two
proteins are distinctly regulated, sequential activation of E2F-
responsive promoters and, potentially, the specificity as to
which E2F-responsive promoters are activated might be more
tightly regulated during HCMV infection. This additional level
of control could help favor productive infection over the ab-
errant outcome of transformation.
Interestingly, data in our laboratory suggest that neither the
IE1-72 nor the IE2-86 protein interacts with the p130 member
of the pocket protein family (our unpublished data). The p130
protein is thought to be one of the first checkpoints for allow-
ing entry into the cell cycle from quiescence (12, 36, 89) and is,
most likely, an essential and initial target in HCMV infection.
It is possible that regulation of the p130 protein occurs through
a signal transduction pathway activated by virus binding to the
cell or that a third protein is encoded by HCMV that directly
binds p130. HCMV infection may coordinate a sequential dis-
ruption of normal pocket protein function beginning with the
p130 protein and then moving to the pRb and p107 proteins.
These directions are all being actively pursued in our labora-
tory.
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